Tumor cells stimulate osteoclasts to release the ligand interleukin (IL)-19 for the IL receptor 20 subunit β (IL-20RB), which then triggers IL-20RB-expressing tumor cells to initiate downstream JAK1/STAT3 signaling. This evidence concerns the gene IL19 and neoplasm.